Please use this identifier to cite or link to this item:
http://hdl.handle.net/10603/356363
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.coverage.spatial | ||
dc.date.accessioned | 2022-01-18T11:35:22Z | - |
dc.date.available | 2022-01-18T11:35:22Z | - |
dc.identifier.uri | http://hdl.handle.net/10603/356363 | - |
dc.description.abstract | It is clear that there is a growing body of evidence describing the newlineassociation between OSA and the subsequent development of type 2 newlinediabetes. But, the exact pathophysiological mechanism linking OSA as a newlinecausative factor for type 2 diabetes remains still unclear. Pharmacologic newlinetherapy is not part of primary treatment of OSA. These study shows NO may newlinebe the missing link in defective glucose uptake in hypoxic condition. Measures newlineto increase NO may be a unique feature in managing the complexity of the newlinedisease, but hold a considerable potential to reverse insulin resistance. newlineIncreasing NO in OSA participants can lead to novel therapeutic strategy and newlinealso to understand whether NO can be utilised as an assistive tool in the early newlinediagnosis and in prevention of high risk OSA group to develop type 2 diabetes at an early stage .This study proposes to assess role of nitric oxide and insulin newlineresistance in obstructive sleep apnoea population and to study Single newlineNucleotide gene polymorphism in eNOS, HIFA1 and GLUT4 genes. newlineAim newlineThis aim of the present study is to assess the association of genetic newlinevariants of nitric oxide with insulin resistance in obstructive sleep apnoea. newlineThis study newlinemolecular evidence standalone to shows result that hypoxia can be the risk newlinefactor for insulin resistance in turn type 2DM. Awareness among all health newlineprofessionals involved with OSA or diabetes should be educated about the newlinelinks between these two conditions. Pharmacologic therapy still is not part of newlineprimary treatment of OSA participants. Pharmacologic therapy like NO may newlinebe a unique challenge in managing the complexity of the disease, but holds a newlineconsiderable potential to reverse insulin resistance it can lead to novel newlinetherapeutic strategies for pharmacotherapy in OSA. Early identification of newlineobstructive sleep apnoea participants with metabolic dysfunction, like insulin newlineresistance including type 2 diabetes could reduce cardiovascular disease risk newlineand improve the quality of life and also can prevent these chronic diseases. newline | |
dc.format.extent | ||
dc.language | English | |
dc.relation | ||
dc.rights | university | |
dc.title | The role of nitric oxide insulin resistance and genetic factors in obstructive sleep apnoea | |
dc.title.alternative | ||
dc.creator.researcher | K Ramya | |
dc.subject.keyword | Biochemistry and Molecular Biology | |
dc.subject.keyword | Biology and Biochemistry | |
dc.subject.keyword | Life Sciences | |
dc.description.note | ||
dc.contributor.guide | Gowri Sethu | |
dc.publisher.place | Chennai | |
dc.publisher.university | Saveetha University | |
dc.publisher.institution | Department of Physiology | |
dc.date.registered | 2013 | |
dc.date.completed | 2018 | |
dc.date.awarded | 2019 | |
dc.format.dimensions | ||
dc.format.accompanyingmaterial | None | |
dc.source.university | University | |
dc.type.degree | Ph.D. | |
Appears in Departments: | Department of Physiology |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
01_title.pdf.pdf | Attached File | 1.73 MB | Adobe PDF | View/Open |
02_certificate.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
03_declaration.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
04_acknowledgement.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
05_contents.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
06_list_of_tables.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
07_list_of_figures.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
08_abbreviations.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
09_chapter 1.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
10_chapter 2.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
11_chapter 3.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
12_chapter 4.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
13_chapter 5.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
14_chapter 6.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
15_summary and conclusion.pdf.pdf | 1.73 MB | Adobe PDF | View/Open | |
16_bio.pdf.pdf | 1.74 MB | Adobe PDF | View/Open | |
80_recommendation.pdf | 1.73 MB | Adobe PDF | View/Open |
Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).
Altmetric Badge: